Shares of Avantor, Inc. (NYSE:AVTR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $25.50.
A number of brokerages recently commented on AVTR. Barclays cut their target price on Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Stifel Nicolaus reduced their price objective on shares of Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a report on Monday, February 10th. Royal Bank of Canada decreased their target price on shares of Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a research report on Monday, February 10th. Wells Fargo & Company dropped their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Finally, Morgan Stanley decreased their price objective on Avantor from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday, February 10th.
Insider Buying and Selling
Institutional Investors Weigh In On Avantor
Several institutional investors have recently modified their holdings of the business. MassMutual Private Wealth & Trust FSB raised its position in shares of Avantor by 99.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after acquiring an additional 625 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of Avantor by 106.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock valued at $34,000 after acquiring an additional 830 shares during the period. Global Retirement Partners LLC raised its position in shares of Avantor by 76.7% in the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock valued at $52,000 after acquiring an additional 1,067 shares during the period. UMB Bank n.a. boosted its stake in Avantor by 56.3% during the 4th quarter. UMB Bank n.a. now owns 2,981 shares of the company’s stock worth $63,000 after acquiring an additional 1,074 shares during the last quarter. Finally, AlphaQuest LLC acquired a new position in Avantor during the fourth quarter valued at approximately $65,000. Institutional investors and hedge funds own 95.08% of the company’s stock.
Avantor Price Performance
Shares of Avantor stock opened at $15.93 on Friday. The firm has a fifty day moving average price of $17.08 and a two-hundred day moving average price of $20.63. Avantor has a fifty-two week low of $13.80 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.07 and a quick ratio of 0.70. The company has a market cap of $10.85 billion, a PE ratio of 15.32, a price-to-earnings-growth ratio of 1.55 and a beta of 1.24.
Avantor (NYSE:AVTR – Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same quarter last year, the business earned $0.22 EPS. Analysts expect that Avantor will post 1.06 EPS for the current year.
About Avantor
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Featured Articles
- Five stocks we like better than Avantor
- What is a Death Cross in Stocks?
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Are Tariffs Threatening Disney’s Comeback Story?
- When to Sell a Stock for Profit or Loss
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.